Biomerica Research Development vs Interest Expense Analysis
BMRA Stock | USD 0.32 0.02 5.88% |
Biomerica financial indicator trend analysis is way more than just evaluating Biomerica prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biomerica is a good investment. Please check the relationship between Biomerica Research Development and its Interest Expense accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomerica. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.
Research Development vs Interest Expense
Research Development vs Interest Expense Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biomerica Research Development account and Interest Expense. At this time, the significance of the direction appears to have very week relationship.
The correlation between Biomerica's Research Development and Interest Expense is 0.22. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Interest Expense in the same time period over historical financial statements of Biomerica, assuming nothing else is changed. The correlation between historical values of Biomerica's Research Development and Interest Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Biomerica are associated (or correlated) with its Interest Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Expense has no effect on the direction of Research Development i.e., Biomerica's Research Development and Interest Expense go up and down completely randomly.
Correlation Coefficient | 0.22 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Research Development
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Most indicators from Biomerica's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biomerica current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomerica. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.At present, Biomerica's Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 9.1 M, whereas Selling General Administrative is forecasted to decline to about 5.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 3.0M | 446K | 611K | 580.5K | Total Revenue | 18.9M | 5.3M | 5.4M | 7.6M |
Biomerica fundamental ratios Correlations
Click cells to compare fundamentals
Biomerica Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biomerica fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 17.3M | 11.8M | 11.4M | 14.5M | 9.3M | 7.4M | |
Other Current Liab | 278.6K | 213.3K | 848.6K | 1.2M | 1.5M | 1.6M | |
Total Current Liabilities | 1.5M | 1.3M | 2.0M | 1.9M | 2.2M | 1.3M | |
Total Stockholder Equity | 14.2M | 9.2M | 8.3M | 11.7M | 6.6M | 4.5M | |
Property Plant And Equipment Net | 2.0M | 1.9M | 1.5M | 1.2M | 943K | 693.1K | |
Net Debt | (6.9M) | (2.6M) | (4.5M) | (8.6M) | (3.4M) | (3.2M) | |
Retained Earnings | (21.9M) | (28.4M) | (35.1M) | (42.2M) | (48.2M) | (45.8M) | |
Cash | 8.6M | 4.2M | 5.9M | 9.7M | 4.2M | 2.2M | |
Non Current Assets Total | 2.5M | 2.6M | 1.9M | 1.7M | 1.5M | 1.4M | |
Non Currrent Assets Other | 168.2K | 264.2K | 95.6K | 79K | 203K | 166.8K | |
Cash And Short Term Investments | 8.6M | 4.2M | 5.9M | 9.7M | 4.2M | 2.2M | |
Net Receivables | 1.8M | 1.5M | 773.8K | 722K | 947K | 950.1K | |
Common Stock Shares Outstanding | 10.2M | 11.9M | 12.7M | 14.2M | 16.8M | 17.7M | |
Liabilities And Stockholders Equity | 17.3M | 11.8M | 11.4M | 14.5M | 9.3M | 7.4M | |
Non Current Liabilities Total | 1.6M | 1.3M | 1.0M | 785K | 459K | 436.1K | |
Inventory | 2.9M | 3.2M | 2.4M | 2.1M | 2.4M | 2.2M | |
Other Current Assets | 1.5M | 370.3K | 320.7K | 300K | 238K | 285.8K | |
Other Stockholder Equity | 35.2M | 38.8M | 42.4M | 52.7M | 53.5M | 56.2M | |
Total Liab | 3.0M | 2.6M | 3.0M | 2.7M | 2.7M | 1.5M | |
Property Plant And Equipment Gross | 2.0M | 1.9M | 3.5M | 3.2M | 3.2M | 3.4M | |
Total Current Assets | 14.8M | 9.2M | 9.4M | 12.8M | 7.7M | 6.0M | |
Accumulated Other Comprehensive Income | (39.8K) | (48.0K) | (73.9K) | (110K) | (102K) | (107.1K) | |
Accounts Payable | 986.7K | 431K | 736K | 344K | 288K | 565.5K | |
Intangible Assets | 168.7K | 294.8K | 170K | 165K | 212K | 273.3K | |
Common Stock Total Equity | 711.0K | 774.2K | 939.2K | 984.6K | 1.1M | 622.7K | |
Common Stock | 939.2K | 984.6K | 1.0M | 1.3M | 1.5M | 1.6M | |
Other Assets | 168.2K | 264.2K | 363.0 | 79K | 90.9K | 86.3K | |
Property Plant Equipment | 2.0M | 1.9M | 1.5M | 1.2M | 1.4M | 1.5M | |
Net Tangible Assets | 14.0M | 8.9M | 8.2M | 11.6M | 13.3M | 7.8M | |
Net Invested Capital | 14.2M | 9.2M | 8.3M | 11.7M | 6.6M | 8.6M | |
Net Working Capital | 13.3M | 7.9M | 7.4M | 10.9M | 5.5M | 7.6M | |
Capital Stock | 964.9K | 984.6K | 1.0M | 1.3M | 1.5M | 1.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biomerica offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomerica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomerica Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomerica Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomerica. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomerica. If investors know Biomerica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomerica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 0.327 | Quarterly Revenue Growth 0.055 | Return On Assets (0.39) | Return On Equity (0.76) |
The market value of Biomerica is measured differently than its book value, which is the value of Biomerica that is recorded on the company's balance sheet. Investors also form their own opinion of Biomerica's value that differs from its market value or its book value, called intrinsic value, which is Biomerica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomerica's market value can be influenced by many factors that don't directly affect Biomerica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomerica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomerica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomerica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.